ArticleBritish journal of clinical pharmacology2016
Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs.
Article in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs.Translational psychiatry · 2017Pooled it
- Twenty-Year Trends in Antipsychotic Utilization in Serbia: A Nationwide Drug Utilization Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Guideline adherence for cardiometabolic monitoring of patients prescribed antipsychotic medications in primary care: a retrospective observational study.International journal of clinical pharmacy · 2023Observational
- [Antipsychotic prescription prevalence and metabolic monitoring of patients under chronic treatment].Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2021Article
- 'Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study'.Epidemiology and psychiatric sciences · 2020Article
- Article
- Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016.British journal of clinical pharmacology · 2019Article
- The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?Drug safety · 2019Review
- Use of psychoactive drugs predicts functional disability among older adults.Revista de saude publica · 2019Article
- Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand.Therapeutic advances in drug safety · 2019Article
- Prevalence of use of antipsychotic drugs in the elderly in Catalonia.European journal of clinical pharmacology · 2018Article
- Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study.Drug safety · 2018Article
- Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.Annals of translational medicine · 2018Article
- An error in the article by Oteri et al: 'Prescribing pattern of antipsychotic drugs during the years 1996-2010'.British journal of clinical pharmacology · 2017Article
- Erratum.British journal of clinical pharmacology · 2017Article
- Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs.British journal of clinical pharmacology · 2016Article
Corrections and comments
- Commented on by
- Erratum issuedErratum.2017
Authors and funding
14 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntipsychotic drugs (APDs) are used to treat several mental illnesses. Some APDs have long been known to be associated with QT prolongation, potentially leading to torsades de pointes (TdP) and sudden cardiac death (SCD). In 2005, thioridazine was withdrawn because of the risk of SCD, bringing further attention to the arrhythmogenic potential of APDs.
aimThe aim of the current study was to evaluate the use of APDs in five European countries during the years 1996-2010.
methodsA cohort study was conducted using prescription/dispensing data from seven healthcare databases [the AARHUS University Hospital Database (Denmark), the German Pharmacoepidemiological Research Database (GePaRD) (Germany), Health Search Database/Thales (HSD) and Emilia Romagna Regional Database (ERD) (Italy), PHARMO Database Network and Integrated Primary Care Information (IPCI) (the Netherlands) and The Health Improvement Network (THIN) (the UK), covering a population of 27 million individuals. The annual prescription rate of APDs was measured overall and for individual medications. APDs were classified as torsadogenic according to the Arizona-CERT list. All analyses were stratified by age, gender and calendar year.
resultsA total of 559 276 person-years (PYs) of exposure to APDs was captured. The crude annual prescription rate of APD use ranged from 3.0/1000 PYs in ERD to 7.7/1000 PYs in AARHUS. Among APDs with established torsadogenic potential, thioridazine was the most frequently used medication in the UK. Haloperidol was commonly prescribed in Italy and the Netherlands. The use of APDs with torsadogenic potential was much higher in elderly patients.
conclusionsSubstantial use of APDs with torsadogenic potential has been reported in Europe in recent years, in spite of increasing concerns about their arrhythmogenic potential. This use was even greater in elderly patients, who are at higher risk of SCD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.